Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and autoimmune diseases. The company utilizes three proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its lead product candidate, JANX007, is a prostate-specific membrane antigen (PSMA) TRACTr in Phase 1 trials for metastatic castration-resistant prostate cancer. JANX008 is an epidermal growth factor receptor (EGFR) TRACTr in Phase 1 trials for multiple solid tumors. JANX011 is a CD19-ARM candidate in Phase 1 trials for autoimmune diseases, and JANX013 has entered Phase 1 clinical trials. The company was founded in 2017 and completed its initial public offering in June 2021.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage januxrx.com
Sector Healthcare IR page investors.januxrx.com/overview/default.aspx
Tags
immunotherapy, t-cell engagers, bispecific antibodies, prostate cancer, solid tumors, autoimmune diseases, clinical-stage, oncology, TRACTr, TRACIr, ARM, JANX007, JANX008, JANX011, JANX013
Press page —

Metrics

Valuation  
Market cap $ 1.057B
Market cap (USD) $ 1.057B
P/E -10.87
PEG —
P/BV 1.16
P/S 105.71
P/OCF -19.73
P/FCF -19.52
Dividend yield —
Turnover / mcap —
Returns  
ROE -11.5%
ROI -12.3%
ROIC -12.8%
Profit margin -1,136.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 23
Quality score -81.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 10M 10.588M 8.083M 8.612M 3.637M 0
Net profit -113.625M -68.994M -58.293M -63.059M -32.672M 0
Free cash flow -83.278M -44.173M -52.425M -49.367M -18.458M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 13.8 53.54 10.73 13.17 19.73 —
Price performance 12m -0.74 3.99 -0.19 -0.33 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 8M 0.00 0.00 0.00 — 0.00
↳ YoY growth -100.0%
Lease liabilities (USD) 0.00 194,000 25.3M 24.5M 23M 22.1M
Cash and deposits (USD) 7.81M 35.6M 51.4M 19.2M 431M 52.3M
Right-of-use assets (USD) 0.00 185,000 22.3M 20.8M 19.3M 18.4M
Cash flow detail
Operating cash flow (USD) -4.37M -17M -42.9M -50.6M -43.8M -82.2M
Purchases of property, plant and equipment (USD) 0.00 -1.48M -6.45M -1.85M -359,000 -1.04M
Change in receivables (cash effect) (USD) -8M 8M 0.00 — — —
Change in payables (cash effect) (USD) 14,000 2.14M -294,000 277,000 1.58M 977,000
Share-based compensation (USD) 72,000 6.91M 17.2M 20M 33M 40.2M
Operating cash flow before change in receivables (USD) 3.63M -25M -42.9M — — —
Free cash flow (OCF - PPE - intangibles) (USD) -4.37M -18.5M -49.4M -52.4M -44.2M -83.3M
Income detail
Research and development expense (USD) 3.04M 26.2M 53.4M 54.9M 68.4M 126M
↳ 5y CAGR +110.6%
Total comprehensive income (USD) -6.78M -32.9M -64.3M -56.1M -67.5M -111M
Reported Mar 18, 2022 Mar 18, 2022 Mar 10, 2023 Mar 8, 2024 Feb 27, 2025 May 7, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026

•First patient dosed in the Phase 1 study evaluating JANX013 in combination with JANX007

•JANX007 Phase 1b development continues across taxane-naïve monotherapy and darolutamide combination cohorts

•JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC)

•Strong balance sheet with $945.7 million in cash, cash equivalents and short-term investments supports advancement of multiple clinical-stage programs

SAN DIEGO, November 5, 2026 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update.

“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux.

September 14, 2026

- JANX013 is a novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific designed to further enhance the durability of anti-tumor immune responses in combination with Janux’s PSMA-targeted T cell engager candidates

- Study will evaluate JANX013 in combination with Janux’s PSMA-targeted T cell engager candidates, initially JANX007, in patients with metastatic castration-resistant prostate cancer (mCRPC)

- JANX013 is designed to further differentiate Janux’s prostate cancer franchise through tumor-activated CD28 co-stimulation

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).

The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation. Over time, Janux intends to evaluate JANX013 in combination with additional candidates within its prostate cancer portfolio.

Prostate cancer is the most commonly diagnosed cancer in men, excluding skin cancers. Clinical experience with Janux's PSMA-targeted T cell engager candidates has demonstrated the potential of tumor-activated T cell immunotherapy in patients with metastatic castration-resistant prostate cancer. CD28 is a key co-stimulatory receptor involved in T-cell activation, expansion, and persistence. JANX013 is designed to selectively deliver CD28 co-stimulation within the tumor microenvironment using Janux’s proprietary tumor-activation technology, with the goal of further enhancing the durability of anti-tumor immune responses while minimizing systemic CD28 activation.

"Co-stimulation plays a critical role in promoting sustained T-cell function and persistence," said Simon Butikofer, M.D., Vice President, Clinical Development. "JANX013 is designed to selectively deliver tumor-restricted co-stimulation in combination with our CD3 T cell engagers, with the goal of extending the durability of anti-tumor immune responses."

"The initiation of the JANX013 clinical program represents an important milestone in the continued evolution of our prostate cancer franchise," said David Campbell, Ph.D., President and Chief Executive Officer of Janux Therapeutics. "By combining complementary tumor-activated immunotherapies, we believe we have an opportunity to further improve long-term outcomes for patients with prostate cancer."

The Phase 1 clinical trial (NCT07813637) is a first-in-human, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013 in combination with JANX007 in adult patients with mCRPC. In addition to evaluating safety, the study is intended to evaluate biomarkers of immune activation, including T-cell expansion and persistence, to characterize the effects of tumor-restricted CD28 co-stimulation and inform future clinical development of JANX013.

For additional information about the study, please visit ClinicalTrials.gov using the identifier NCT07813637.

About Janux Therapeutics

Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.

Janux’s lead clinical candidate, JANX007, is a PSMA-targeted TRACTr being investigated in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also advancing additional PSMA-targeted programs, including JANX014, a double-masked PSMA TRACTr being evaluated in a Phase 1 clinical trial, and JANX013, a CD28 co-stimulatory TRACIr being evaluated in a Phase 1 clinical trial in combination with JANX007.

Beyond its prostate cancer programs, Janux’s pipeline includes JANX011, a CD19-targeted ARM being evaluated in a Phase 1 clinical trial in healthy adult volunteers for potential treatment of autoimmune diseases. Janux continues to generate additional TRACTr, TRACIr, and ARM programs for potential future development.

August 6, 2026

  • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts
  • JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC)
  • JANX011 Phase 1 healthy volunteer study progressing as planned
  • JANX013 remains on track for clinical initiation in the second half of 2026
  • Strong balance sheet supports advancement of multiple clinical programs with $970.9 million in cash, cash equivalents and short-term investments at end of 2Q26

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update.

"During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "Enrollment continues across our prostate cancer programs, including JANX007 and JANX014, and we remain on track to initiate clinical development of JANX013 later this year. We also continue to make progress with JANX011 in healthy volunteers as we advance our autoimmune disease pipeline."

BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS:

Clinical & Pipeline Progress

  • JANX007 (PSMA-TRACTr) continues to enroll in its Phase 1b trial in metastatic castration-resistant prostate cancer (mCRPC), with ongoing dose optimization and expansion in taxane-naïve patients.
    • An expansion cohort evaluating JANX007 in combination with darolutamide, an androgen receptor pathway inhibitor, is actively enrolling in taxane-naïve mCRPC.
  • JANX014 (PSMA-TRACTr), a double-masked tumor-activated T cell engager, continues enrollment in its Phase 1 clinical study designed to evaluate safety, pharmacokinetics and preliminary antitumor activity.
  • JANX011 (CD19-ARM) continues enrolling in its Phase 1 clinical trial in healthy volunteers.
  • The Company continues to advance additional TRACTr, TRACIr and ARM programs for potential future development.

Upcoming Milestones

  • Initial clinical data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026.
  • Clinical initiation of JANX013, a PSMA-targeted CD28 costimulatory TRACIr, expected in the second half of 2026.
  • Additional clinical data for JANX007 expected to be announced at a future medical congress in the first half of 2027.

SECOND QUARTER 2026 FINANCIAL RESULTS:

  • Cash and cash equivalents and short-term investments: As of June 30, 2026, Janux reported cash and cash equivalents and short-term investments of $970.9 million, compared to $966.6 million on December 31, 2025.
  • Research and development expenses: Research and development expenses were $31.0 million for the quarter ended June 30, 2026, compared to $34.7 million for the comparable period in 2025.
  • General and administrative expenses: General and administrative expenses were $11.0 million for the quarter ended June 30, 2026, compared to $10.5 million for the comparable period in 2025.
  • Net loss: Net loss was $22.0 million for the quarter ended June 30, 2026, compared to $33.9 million for the comparable period in 2025.

About Janux Therapeutics

Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.

Janux’s lead clinical candidate, JANX007, is a PSMA-targeted TRACTr being investigated in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also advancing additional PSMA-targeted programs, including JANX014, a double-masked PSMA TRACTr being evaluated in a Phase 1 clinical trial, and JANX013, a CD28 co-stimulatory TRACIr designed for combination with JANX007.

Beyond its prostate cancer programs, Janux’s pipeline includes JANX011, a CD19-targeted ARM being evaluated in a Phase 1 clinical trial in healthy adult volunteers for potential treatment of autoimmune diseases. Janux continues to generate additional TRACTr, TRACIr, and ARM programs for potential future development.

Prompts

Janux Therapeutics, Inc. (ticker JANX), listed in United States.

ETFs Holding Janux Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.99% 196,534 $ 3.581M Aug 31, 2026
CANC 0.47% 53,953 $ 983.024K Aug 31, 2026
FMED 0.42% 11,754 $ 214.158K Aug 31, 2026
ESSC 0.12% 2,826 $ 42.87K Jul 31, 2026
AVSC 0.03% 74,807 $ 816.892K Nov 16, 2026
RESM 0.03% 67 $ 1,029.12 Jun 30, 2026
FBCG 0.03% 123,298 $ 1.87M Jul 31, 2026
DFAS 0.01% 236,152 $ 2.715M Nov 12, 2026
DXUV 0.00% 10,716 $ 123.18K Nov 12, 2026
DFUS 0.00% 6,753 $ 77.626K Nov 12, 2026
DFAU 0.00% 1,868 $ 21.473K Nov 12, 2026
DFAC 0.00% 11,537 $ 132.618K Nov 12, 2026
AVUS 0.00% 10,819 $ 118.143K Nov 16, 2026